Please Wait
Applying Filters...
menu
    • menu
    CDMO Activity Tracker: Lupin’s CDMO commissions oncology block in India; Cambrex, Axplora, Hovione expand operations

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 415Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    29/11/2025 Enaltec Labs
    India
    		 ENALTEC LABS PRIVATE LIMITED Navi Mumbai IN R0-CEP 2019-341 - Rev 00 Dronedarone hydrochloride 2023-04-11 Valid Chemical 3039
    29/11/2025 Aurobindo Pharma Limited
    India
    		 APITORIA PHARMA PRIVATE LIMITED Hyderabad IN CEP 2020-051 - Rev 01 Dronedarone hydrochloride 2024-01-16 Valid Chemical 3039
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.